agilon health, inc.AGL

agilon health’s March-quarter 10-Q shows a company that can spin $1.42bn of revenue into $48.9m of net income and still only cough up $23.7m of operating cash flow, leaving $140m in cash looking less like a war chest and more like the float a doctor’s surgery keeps on hand for the next Medicare payment cycle. Operating income clocked in at just $4m, which is polite enough to keep the lights on but won’t cover the $1.32bn in liabilities that the balance sheet cheerfully carries. Diluted earnings of $2.94 per share are spread across 16.7m shares, a structure that leaves little room for big capital returns while the working capital is already stretched.

agilon’s public materials still sell the idea of a national crusade to replace fee-for-service medicine with value-based care, but the 10-Q quietly admits the operating engine is still a small-bore $4m profit machine. The company’s own website and newsroom promise empowered primary-care physicians and transformed care delivery, yet the latest filings don’t include a new product approval, a revenue milestone beyond $1.42bn, or any evidence that the polished platform story is actually widening the profit margin. The investor email signup page exists mainly to harvest leads for a business whose most concrete recent update is a 2024 ACO REACH model results release.

Revenue from Contract with Customer, Excluding Assessed Tax sat at $1.42bn for the quarter ended 31 March 2026. Net income attributable to the parent was $48.9m, operating income was $4.0m, assets totalled $1.50bn, liabilities $1.32bn, cash and equivalents $140.0m, operating cash flow $23.7m, capex $3.1m, diluted EPS $2.94, and the diluted share count 16.7m shares (10-Q, period ending 2026-03-31, SEC EDGAR, https://www.sec.gov/Archives/edgar/data/1831097/000162828026049080/agl-20260717.htm).

agilon describes itself as transforming healthcare for seniors by empowering primary-care physicians to deliver value-based care through partnerships and a platform, a pitch that reads better on the homepage and in press releases than it does in the 10-Q. The company’s own product pages and news archive trumpet heart-failure clinical pathways and ACO REACH results, but none of these updates change the fact that operating income remains a rounding error against liabilities and that the next working-capital crunch could arrive before the next earnings call.

The company’s Form 4 filings show executives and directors continuing to receive shares, a reminder that the optics of insider alignment are still in vogue even as the cash runway stays short. Recent filings include multiple Form 4s in June and July, indicating ongoing equity compensation activity rather than a shift to cash incentives or buybacks (SEC EDGAR Form 4, 2026-06-04, https://www.sec.gov/Archives/edgar/data/1831097/000162828026041025/xslF345X06/wk-form4_1780624633.xml; 2026-06-05, https://www.sec.gov/Archives/edgar/data/1831097/000162828026041353/xslF345X06/wk-form4_1780703200.xml; 2026-07-02, https://www.sec.gov/Archives/edgar/data/1831097/000162828026047075/xslF345X06/wk-form4_1783032260.xml; 2026-07-22, https://www.sec.gov/Archives/edgar/data/1831097/000162828026049080/agl-20260717.htm).

If you’re looking for a chart that tracks agilon’s share price, the company’s own investor rail points to its disclosure site rather than to any trading data or charting service. The filings and company facts JSON on SEC EDGAR provide the raw numbers but no forward-looking price levels, so treat any attempt to call support or resistance as pure speculation rather than evidence (SEC EDGAR filings index, https://www.sec.gov/edgar/browse/?CIK=1831097; Company Facts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001831097.json; Submissions JSON, https://data.sec.gov/submissions/CIK0001831097.json).